@article{8f0db54a236f46b4a909ad3ed189d79f,
title = "Editorial: biochemical responses do not tell the whole story in primary biliary cholangitis",
author = "Bowlus, {Christopher L.} and Cynthia Levy",
note = "Funding Information: Declaration of personal interests : Christopher L. Bowlus has served as a speaker, a consultant and an advisory board member for BiomX, Cymabay Therapeutics, Gilead Biosciences, GlaxoSmithKline, and Intercept Pharmaceuticals, and has received research funding from BiomX, Cymabay Therapeutics, Eli Lilly, Genkyotex, Gilead Biosciences, GlaxoSmithKline, Intercept Pharmaceuticals, NGM Biosciences, Novartis, Shire, Takeda, TARGET Pharmasolutions. Cynthia Levy has served as a consultand and advisory member board for Cymabay Therapeutics, GlaxoSmithKline, Cara Therapeutics, Flashlight, Shire and TARGET Pharmasolutions, and has received research funding from Cymabay Therapeutics, Eli Lilly, Genkyotex, Gilead Biosciences, GlaxoSmithKline, Intercept Pharmaceuticals, Novartis, Genfit, Shire, TARGET Pharmasolutions, Cara Therapeutics, Durect and High Tide. ",
year = "2020",
month = jan,
day = "1",
doi = "10.1111/apt.15576",
language = "English (US)",
volume = "51",
pages = "177--178",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "1",
}